Genitourinary · 38 CFR 4.115b · Diagnostic Code 7528

Prostate Cancer VA Disability Rating

By · Last updated 2026-05-22 · Source: 38 CFR 4.115b · Agent Orange status: 38 CFR 3.309(e) (since 1996)

TL;DR. Prostate cancer rates 100% during active malignancy + at least 6 months after treatment ends (DC 7528). A mandatory VA exam at the 6-month mark reduces to residuals-based rating if no recurrence/metastasis. Residuals stack: urinary incontinence (DC 7527, 20-60%), erectile dysfunction (DC 7522 + SMC-K), urethral stricture (DC 7518). Many post-prostatectomy veterans rate 60-80% combined on residuals alone. Prostate cancer is Agent Orange presumptive since 1996 for Vietnam-era, Korean DMZ 1968-1971, Thailand-base, Blue Water Navy, and C-123 aircrew veterans — no nexus opinion needed.

What prostate cancer means in VA disability terms

Prostate cancer is an adenocarcinoma of the prostate gland, the most common solid-tumor malignancy in U.S. men. Diagnosis is established by biopsy after elevated PSA or abnormal DRE. Staging follows the TNM system. The VA does not differentiate by Gleason score, stage, or treatment modality for initial rating purposes — all confirmed prostate cancer rates 100% during active disease.

Full DC 7528 criteria

RatingCriteria
100%Malignant neoplasms of the genitourinary system — including prostate cancer — rate 100% during active disease and for at least 6 months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Following the 6-month period, a mandatory VA examination is conducted. If no local recurrence or metastasis, rating is based on residuals as voiding dysfunction or renal dysfunction (whichever is predominant).

The note to DC 7528 directs raters to evaluate residuals under voiding dysfunction (DC 7527) or renal dysfunction (DC 7541), whichever is the predominant area. In practice, voiding dysfunction is the dominant pathway for post-treatment prostate cancer.

The 6-month residuals transition

At the 6-month mark after treatment ends, the VA conducts a mandatory exam:

The "treatment ended" date is important. For surgery, it's the date of prostatectomy. For radiation, it's the last day of the radiation course. For androgen deprivation therapy (ADT), it's when ADT is discontinued — veterans on continuous ADT remain at 100% as long as treatment continues. For active surveillance ("watchful waiting"), treatment has not ended; the veteran remains at 100% as long as the cancer is monitored as active.

Common residuals (rate each separately)

Urinary incontinence / voiding dysfunction (DC 7527)

The most common residual after radical prostatectomy. Rated based on absorbent material usage:

Erectile dysfunction (DC 7522 + SMC-K)

Post-prostatectomy ED is nearly universal. 0% schedular but ALWAYS triggers SMC-K ($137.55/month in 2026). Some veterans qualify for the 20% schedular if anatomical deformity is documented.

Urethral stricture (DC 7518)

Post-treatment urethral stricture, rated 0-30% based on severity and treatment requirements.

Renal dysfunction (DC 7541)

Rare after prostate cancer but possible after extensive pelvic radiation. Rated 30-100% based on creatinine, BUN, and treatment.

Service-connection paths

Agent Orange presumption (the dominant path)

Since 1996, prostate cancer has been Agent Orange presumptive under 38 CFR 3.309(e). Qualifying service: in-country Vietnam (1962-1975), Korean DMZ (1968-1971), Thailand base perimeter, Blue Water Navy (2019 BWNVAA, retroactive), C-123 aircrew (2015).

Check Agent Orange / PACT Act eligibility →

Camp Lejeune / PACT Act

Prostate cancer is not on the Camp Lejeune presumptive list directly, but the PACT Act expanded coverage to additional cancers and locations.

Direct service connection

For non-Vietnam veterans, direct service connection requires in-service onset (rare for prostate cancer given typical age of onset post-50) or onset within one year of separation under chronic-disease presumption (38 CFR 3.309(a)).

Evidence the VA looks for

Common rating pitfalls

  1. Premature reduction at 6 months. If treatment has not actually ended (continuous ADT, active surveillance), the rating should remain 100%. Appeal premature reductions.
  2. Missing residuals at the reduction exam. The 6-month exam must evaluate all residuals. Bring documentation; refuse to leave with the exam incomplete.
  3. Not claiming ED + SMC-K. Nearly universal post-prostatectomy. Always claim.
  4. Filing without Agent Orange presumption. Vietnam-era veterans should always file under the presumption first.
  5. Accepting a 20% incontinence rating when 40% applies. Pad-usage frequency is the bracket trigger; document accurately.

Worked example

Veteran: Vietnam-era, in-country service 1969-1971. Diagnosed prostate cancer 2023, radical prostatectomy 2024. Post-op residuals: moderate stress incontinence (3 pads/day), erectile dysfunction. PSA undetectable at 6-month mark. Spouse.

  • Active period (during treatment + 6 months post): 100% under DC 7528.
  • At 6-month exam: no recurrence. Rating drops to residuals.
  • Voiding dysfunction (3 pads/day): 40% under DC 7527.
  • ED: 0% schedular + SMC-K.
  • Combined: 40% + SMC-K $137.55/mo.
  • 2026 monthly compensation (veteran + spouse, 40%): $834.16 + $137.55 = $971.71/mo.

During the active 100% period, the same veteran received $3,946/mo + spouse rate. The drop to residuals is substantial — but the 100% period provides ~18 months of higher compensation depending on treatment timeline.

Sources cited in this article

VetDisabilityCalc is an independent reference site operated by Zoom Lifestyle LLC. We are not VA-accredited and we do not prepare or present VA claims.